If you could vote on Brexit now which option would you choose?

Sanofi reports positive Phase I/II interim trial data of Covid-19 vaccine

Sanofi has reported positive interim results from a Phase I/II clinical trial of its messenger ribonucleic acid (mRNA)-based Covid-19 vaccine candidate. These results establish the potential of the lately acquired mRNA and lipid nanoparticle (LNP) platform from Translate Bio and also back Sanofi’s mRNA strategy. According to the preliminary data from the trial, neutralising antibody seroconversion defined as a four-times rise compared to baseline was observed in 91% to 100% of trial subjects two weeks after the second vaccine dose. This trend was noted across all the three dosages tested, Sanofi said. Furthermore, no safety concerns were reported while the tolerability profile was in line with that of other unmodified mRNA Covid-19 vaccines. Sanofi Pasteur Research and Development (R&D) global head Jean-Francois Toussaint said: “We have made an impressive move just nine months after the worldwide proof of concept of mRNA vaccines and only 17 since we started this first mRNA vaccine project.

Pharmaceutical Technology - September 29, 2021

View the full story here: https://www.pharmaceutical-technology.com/news/sanofi-positive-trial-data-covid-19-vaccine/